Yichang HEC

Yichang HEC Changjiang Pharmaceutical is a leading Chinese pharmaceutical company specializing in the development, manufacturing, and commercialization of antiviral drugs and treatments for metabolic diseases. The company is best known for its flagship product, Kewei (oseltamivir phosphate), which holds a dominant market share in China's anti-influenza segment. Beyond antivirals, Yichang HEC has established a significant presence in the endocrine and cardiovascular markets, offering a comprehensive portfolio of insulin products and chronic disease medications. Operating as a core subsidiary of the HEC Group and listed on the Hong Kong Stock Exchange, the company leverages large-scale GMP-compliant manufacturing facilities to serve both domestic and international markets. Its robust pipeline includes a mix of innovative small molecules and biologics aimed at addressing high-prevalence conditions in China.